523 related articles for article (PubMed ID: 12429580)
1. Inhibition of rat platelet aggregation by the diazeniumdiolate nitric oxide donor MAHMA NONOate.
Homer KL; Wanstall JC
Br J Pharmacol; 2002 Dec; 137(7):1071-81. PubMed ID: 12429580
[TBL] [Abstract][Full Text] [Related]
2. Cyclic GMP-independent relaxation of rat pulmonary artery by spermine NONOate, a diazeniumdiolate nitric oxide donor.
Homer KL; Wanstall JC
Br J Pharmacol; 2000 Oct; 131(4):673-82. PubMed ID: 11030715
[TBL] [Abstract][Full Text] [Related]
3. Specific inhibitory effects of the NO donor MAHMA/NONOate on human platelets.
Kobsar A; Simonis S; Klinker E; Koessler A; Kuhn S; Boeck M; Koessler J
Eur J Pharmacol; 2014 Jul; 735():169-76. PubMed ID: 24780647
[TBL] [Abstract][Full Text] [Related]
4. Evidence for a cyclic GMP-independent mechanism in the anti-platelet action of S-nitrosoglutathione.
Gordge MP; Hothersall JS; Noronha-Dutra AA
Br J Pharmacol; 1998 May; 124(1):141-8. PubMed ID: 9630353
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of human platelet aggregation by nitric oxide donor drugs: relative contribution of cGMP-independent mechanisms.
Sogo N; Magid KS; Shaw CA; Webb DJ; Megson IL
Biochem Biophys Res Commun; 2000 Dec; 279(2):412-9. PubMed ID: 11118301
[TBL] [Abstract][Full Text] [Related]
6. Carbon monoxide released by CORM-3 inhibits human platelets by a mechanism independent of soluble guanylate cyclase.
Chlopicki S; Olszanecki R; Marcinkiewicz E; Lomnicka M; Motterlini R
Cardiovasc Res; 2006 Jul; 71(2):393-401. PubMed ID: 16713591
[TBL] [Abstract][Full Text] [Related]
7. Inhibition by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) of responses to nitric oxide-donors in rat pulmonary artery: influence of the mechanism of nitric oxide generation.
Homer KL; Fiore SA; Wanstall JC
J Pharm Pharmacol; 1999 Feb; 51(2):135-9. PubMed ID: 10217311
[TBL] [Abstract][Full Text] [Related]
8. Nitric oxide donors inhibit 5-hydroxytryptamine (5-HT) uptake by the human 5-HT transporter (SERT).
Bryan-Lluka LJ; Papacostas MH; Paczkowski FA; Wanstall JC
Br J Pharmacol; 2004 Sep; 143(1):63-70. PubMed ID: 15302679
[TBL] [Abstract][Full Text] [Related]
9. The soluble guanylyl cyclase inhibitor 1H-[1,2,4]oxadiazolo[4,3,-a] quinoxalin-1-one is a nonselective heme protein inhibitor of nitric oxide synthase and other cytochrome P-450 enzymes involved in nitric oxide donor bioactivation.
Feelisch M; Kotsonis P; Siebe J; Clement B; Schmidt HH
Mol Pharmacol; 1999 Aug; 56(2):243-53. PubMed ID: 10419542
[TBL] [Abstract][Full Text] [Related]
10. Platelet inhibitory effects of the nitric oxide donor drug MAHMA NONOate in vivo in rats.
Homer KL; Wanstall JC
Eur J Pharmacol; 2003 Dec; 482(1-3):265-70. PubMed ID: 14660031
[TBL] [Abstract][Full Text] [Related]
11. Nitric oxide inhibits platelet adhesion to collagen through cGMP-dependent and independent mechanisms: the potential role for S-nitrosylation.
Irwin C; Roberts W; Naseem KM
Platelets; 2009 Nov; 20(7):478-86. PubMed ID: 19852686
[TBL] [Abstract][Full Text] [Related]
12. In vitro comparison of two NONOates (novel nitric oxide donors) on rat pulmonary arteries.
Homer K; Wanstall J
Eur J Pharmacol; 1998 Aug; 356(1):49-57. PubMed ID: 9761423
[TBL] [Abstract][Full Text] [Related]
13. Investigation of the vasorelaxant effects of 3-(5'-hydroxymethyl-2'-furyl)-1-benzyl indazole (YC-1) and diethylamine/nitric oxide (DEA/NO) on the human radial artery used as coronary bypass graft.
Berkan O; Bagcivan I; Kaya T; Yildirim K; Yildirim S; Doğan K
Can J Physiol Pharmacol; 2007 May; 85(5):521-6. PubMed ID: 17632587
[TBL] [Abstract][Full Text] [Related]
14. The effect of 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) and charybdotoxin (CTX) on relaxations of isolated cerebral arteries to nitric oxide.
Onoue H; Katusic ZS
Brain Res; 1998 Feb; 785(1):107-13. PubMed ID: 9526059
[TBL] [Abstract][Full Text] [Related]
15. In vitro inhibition of human and rat platelets by NO donors, nitrosoglutathione, sodium nitroprusside and SIN-1, through activation of cGMP-independent pathways.
Priora R; Margaritis A; Frosali S; Coppo L; Summa D; Di Giuseppe D; Aldinucci C; Pessina G; Di Stefano A; Di Simplicio P
Pharmacol Res; 2011 Sep; 64(3):289-97. PubMed ID: 21539916
[TBL] [Abstract][Full Text] [Related]
16. Benzodifuroxan as an NO-dependent activator of soluble guanylate cyclase and a novel highly effective inhibitor of platelet aggregation.
Bussygina OG; Pyatakova NV; Khropov YV; Ovchinnikov IV; Makhova NN; Severina IS
Biochemistry (Mosc); 2000 Apr; 65(4):457-62. PubMed ID: 10810184
[TBL] [Abstract][Full Text] [Related]
17. N-acetyl-L-cysteine exerts direct anti-aggregating effect on human platelets.
Anfossi G; Russo I; Massucco P; Mattiello L; Cavalot F; Trovati M
Eur J Clin Invest; 2001 May; 31(5):452-61. PubMed ID: 11380598
[TBL] [Abstract][Full Text] [Related]
18. Interference of neutrophil-platelet interaction by YC-1: a cGMP-dependent manner on heterotypic cell-cell interaction.
Liao CH; Cheng JT; Teng CM
Eur J Pharmacol; 2005 Sep; 519(1-2):158-67. PubMed ID: 16112105
[TBL] [Abstract][Full Text] [Related]
19. The nitric oxide donors, SNAP and DEA/NO, exert a negative inotropic effect in rat cardiomyocytes which is independent of cyclic GMP elevation.
Sandirasegarane L; Diamond J
J Mol Cell Cardiol; 1999 Apr; 31(4):799-808. PubMed ID: 10329207
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanisms underlying rat mesenteric artery vasorelaxation induced by the nitric oxide-independent soluble guanylyl cyclase stimulators BAY 41-2272 [5-cyclopropyl-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-4-ylamine] and YC-1 [3-(5'-hydroxymethyl-2'-furyl)-1-benzyl Indazole].
Teixeira CE; Priviero FB; Webb RC
J Pharmacol Exp Ther; 2006 Apr; 317(1):258-66. PubMed ID: 16352702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
